Efficacy of pharmacologic treatment in tinnitus patients without specific or treatable origin: a network meta-analysis of randomised controlled trials by Chen, Jiann-Jy et al.
ARTICLE IN PRESS
JID: ECLINM [m5G;August 13, 2021;13:40]
EClinicalMedicine 000 (2021) 101080
Contents lists available at ScienceDirect
EClinicalMedicine
journal homepage: https://www.journals.elsevier.com/eclinicalmedicineResearch PaperEfficacy of pharmacologic treatment in tinnitus patients without specific
or treatable origin: A network meta-analysis of randomised controlled
trials
Jiann-Jy Chena,b,1, Yen-Wen Chenb,1, Bing-Yan Zengc,1, Chao-Ming Hungd,e,1,
Bing-Syuan Zengc, Brendon Stubbsf,g, Andre F. Carvalhoi, Trevor Thompsonk,
Michael Roereckel, Kuan-Pin Sum,n,o,f, Yu-Kang Tup,q, Yi-Cheng Wur, Lee Smiths,
Tien-Yu Chent,u, Pao-Yen Linv,w, Chih-Sung Liangx,y, Chih-Wei Hsuv, Shih-Pin Hsuz,
Hung-Chang Kuoz, Ming-Kung Wuv,*, Ping-Tao Tsengb,aa,ab,*
aDepartment of Otorhinolaryngology, E-Da Cancer Hospital, Kaohsiung, Taiwan
b Prospect Clinic for Otorhinolaryngology & Neurology, Kaohsiung City, Taiwan
c Department of Internal Medicine, E-Da Hospital, Kaohsiung, Taiwan
d Division of General Surgery, Department of Surgery, E-Da Cancer Hospital, Kaohsiung, Taiwan
e School of Medicine, College of Medicine, I-Shou University, Kaohsiung, Taiwan
f Department of Psychological Medicine, Institute of Psychiatry, Psychology and Neuroscience, King’s College London, London, United Kingdom
g Physiotherapy Department, South London and Maudsley NHS Foundation Trust, London, United Kingdom
i IMPACT (Innovation in Mental and Physical Health and Clinical Treatment) Strategic Research Centre, School of Medicine, Barwon Health, Deakin University, Gee-
long, VIC, 3220, Australia
k Centre for Chronic Illness and Ageing, University of Greenwich, London, UK
l Institute for Mental Health Policy Research, Campbell Family Mental Health Research Institute, Centre for Addiction and Mental Health (CAMH), Dalla Lana School
of Public Health (DLSPH), University of Toronto, Abbreviation:
m Department of Psychiatry & Mind-Body Interface Laboratory (MBI-Lab), China Medical University Hospital, Taichung, Taiwan
n College of Medicine, China Medical University, Taichung, Taiwan
o An-Nan Hospital, China Medical University, Tainan, Taiwan
p Institute of Epidemiology & Preventive Medicine, College of Public Health, National Taiwan University, Taipei, Taiwan
q Department of Dentistry, National Taiwan University Hospital, Taipei, Taiwan
r Department of Sports Medicine, Landseed International Hospital, Taoyuan, Taiwan
s The Cambridge Center for Sport and Exercise Sciences, Anglia Ruskin University, Cambridge, United Kingdom
t Department of Psychiatry, Tri-Service General Hospital, School of Medicine, National Defense Medical Center, Taipei, Taiwan
u Institute of Brain Science, National Yang Ming Chiao Tung University, Taipei, Taiwan
v Department of Psychiatry, Kaohsiung Chang Gung Memorial Hospital and Chang Gung University College of Medicine, Kaohsiung, Taiwan
w Institute for Translational Research in Biomedical Sciences, Kaohsiung Chang Gung Memorial Hospital and Chang Gung University College of Medicine, Kaoh-
siung, Taiwan
x Department of Psychiatry, Beitou branch, Tri-Service General Hospital, School of Medicine, National Defense Medical Center, Taipei, Taiwan
y Graduate Institute of Medical Sciences, National Defense Medical Center, Taipei, Taiwan
z Department of Neurology, E-Da hospital/School of medicine, I-Shou university, Kaohsiung, Taiwan
aa Institute of Biomedical Sciences, National Sun Yat-sen University, Kaohsiung, Taiwan
ab Department of Psychology, College of Medical and Health Science, Asia University, Taichung, TaiwanAbbreviations: 95%CIs, 95% confidence intervals; ACA, Acamprosate; ALP, Alprazolam; ALVit
epine; CHL, Chlorpheniramine; ClD, Clonazepam plus deanxit; CLES, Common language effe
biloba; DeLid, Intra-tympanic dexamethasone injection plus lidocaine; DeMel, Intra-tympan
tion; Gab, gabapentin; GABA, gamma-Aminobutyric acid; GaLid, gabapentin plus intraderma
ment, Development and Evaluation; KRG, Korean red ginseng; Mel, Melatonin alone; MeSu
Misoprostol; NER, Neramexane; NMA, Network meta-analysis; NOR, Nortriptyline; OXC, Oxc
plus vitamin E; Pen, Pentoxifylline; PIR, Piribedil; PLA, placebo; PRA, Pramipexole; PRISMA, P
controlled trials; RR, Rate ratio; SER, Sertraline; SMD, Standardized mean difference; SUCRA
Trazodone; TRI, Postaurical subcutaneous triamcinolone injection; VAR, Vardenafil; VAS, V
supplementation
* Corresponding author.
E-mail addresses: ducktseng@gmail.com, mingkung180@gmail.com (M.-K. Wu).
1 contributed equally as first author
https://doi.org/10.1016/j.eclinm.2021.101080
2589-5370/© 2021 The Author(s). Published by Elsevier Ltd. This is an open access article und
Please cite this article as: J.-J. Chen et al., Efficacy of pharmacologic tr
network meta-analysis of randomised controlled trials, EClinicalMedicineC, Alpha-lipoic acid plus vitamin C; AMI, Amitriptyline; Bet, Betahistine; Car, Carbamaz-
ct size; CLO, Clonazepam; DeGin, Intra-tympanic dexamethasone injection plus ginkgo
ic dexamethasone injection plus melatonin; DEX, Intra-tympanic dexamethasone injec-
l lidocaine injection; Gin, ginkgo biloba; GRADE, Grading of Recommendations Assess-
l, Melatonin and sulodexide; Met, Intra-tympanic methylprednisolone injection; MIS,
arbazepine; Ozone, Ozone exposure; PAR, Paroxetine; PaVitE, papaverine hydrochloride
referred Reporting Items for Systematic Reviews and Meta-Analyses; RCT, Randomised
, Surface under the cumulative ranking curve; THI, Tinnitus handicap inventory; TRA,
isual analogue scale; VePar, Vestipitant and paroxetine; VES, Vestipitant; Zinc, Zinc
er the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/)
eatment in tinnitus patients without specific or treatable origin: A
(2021), https://doi.org/10.1016/j.eclinm.2021.101080
ARTICLE IN PRESS
JID: ECLINM [m5G;August 13, 2021;13:40]
2 J.-J. Chen et al. / EClinicalMedicine 00 (2021) 101080A R T I C L E I N F O
Article History:
Received 22 May 2021
Revised 27 July 2021
Accepted 27 July 2021
Available online xxxResearch in context
Evidence before this study
Although tinnitus has a high pre
complications, tinnitus manag
port and psychological therap
and expensive. Several new
designed for tinnitus patients
mary tinnitus) have been dev
superiority remain unclear.
Added value of this study
Based on 36 randomized cont
pants, pharmacologic interven
(for example, amitriptyline, aca
those with anti-inflammation/a
intra-tympanic dexamethasone
were associated with superior im
and response rate compared
patients without specific or trea
treatments were associated wi
cebo/control.
Implications of all the available e
The pharmacologic manageme
effects (for example, amitriptyl
tin) and those with anti-inflam
example, intra-tympanic dexa
melatonin) appear to serve as
ments for tinnitus without spe
mary tinnitus) in situations w
psychologic therapy was unava
Please cite this article as: J.-J. Ch
network meta-analysis of randomA B S T R A C T
Background: Although tinnitus has a prevalence between 20 and 42.8%, the currently recommended manage-
ment for tinnitus, such as tinnitus support and psychologic therapies, are relatively time-consuming and expensive. Sev-
eral new pharmacologic treatments designed for tinnitus patients without specific origin had been developed but their
efficacy remains unclear.
Methods: The current Network Meta-Analysis (NMA) of randomised controlled trials (RCTs) was conducted to
evaluate the efficacy of different pharmacologic treatments for tinnitus management in tinnitus patients without specific
or treatable origin (i.e. primary tinnitus). Databases were searched from inception to April 5th, 2021. All network meta-
analytic procedures were conducted under the frequentist model. We calculated the effect size of outcomes with differ-
ent rating scales with standardized mean difference. PROSPERO registration: CRD42020177742.
Findings: Overall, 36 RCTs were included with 2,761 participants. The main results revealed that pharmaco-
logic interventions with brain-acting effect (for example, amitriptyline, acamprosate, and gabapentin) and those with
anti-inflammation/anti-oxidant effect (for example, intra-tympanic dexamethasone injection plus oral melatonin) were
associated with superior improvement in tinnitus severity and response rate compared to placebo/control. Oral amitrip-
tyline were associated with the highest improvement in tinnitus severity and the fourth highest response rate. None of
the investigated interventions was associated with different changes in quality of life compared to placebo/control. All
the investigated treatments were associated with similar drop-out rate to placebo/control.
Interpretation: The current NMA suggests a potential role for treatments with brain-acting effect (for exam-
ple, amitriptyline, acamprosate, and gabapentin) or anti-inflammation/anti-oxidant effect (for example, intra-tympanic
dexamethasone injection plus oral melatonin) as the preferable effective treatments for tinnitus without specific or treat-
able origin.
Funding: none.© 2021 The Author(s). Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license
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Among the adult population, tinnitus has a global prevalence of
approximately 20% [1]. Moreover, the economic burden to manage
tinnitus resulted in a total healthcare bill of GB£750 million per
annum in the United Kingdom in 2016 [2] and estimated healthcare
costs at US$660 per patient per year in the United States [3]. Tinnitus
has been recognised as a difficult disease to define and manage owing
to controversy regarding its definition and treatment [4].
Several potential aetiological sources underlie tinnitus symptoms
development, including [1] the peripheral auditory system [5], [2]
the tinnitus auditolimbic dopaminergic pathway [6] or [3] overt oxi-
dative stress or imbalance of antioxidant enzyme [5,7]. Although
somatic treatments can be effective in cases of tinnitus with a specific
origin (such as palatal myoclonus, deafferentation of the auditory
system, loss of cochlear hair cells, and ototoxic drugs), the efficacy of
traditional pharmacologic treatment to reduce tinnitus severity has
been controversial in tinnitus with unknown etiology [1,8].
The currently recommended management to tinnitus, such as tin-
nitus support and psychologic therapies, are relatively time-consum-
ing and expensive [8,9]. Furthermore, the management of tinnitus
support and psychologic therapy involved prolonged person-to-per-
son contact, which would increase the risk of infection during the
CoVID19 pandemic era. Several pharmacologic treatments or nutrient
supplementation strategies have been developed in recent decades.
For example, antioxidant supplementation, such as melatonin, ginkgo
biloba, and vitamin C, have been widely investigated for tinnitus
management [10]. Local treatment with steroid injection has also
been considered as an alternative to traditional oral pharmacologic
treatment. Furthermore, in tinnitus patients without specific or treat-
able origin, there were abnormal hyperactivity in brain multiple
regions [11]. Therefore, new pharmacologic strategy for managing
brain abnormal hyperactivities had been proposed [12]. However,
there is a lack of clarity regarding the evidence about the efficacy for
most of these alternative treatments.
Previous pairwise meta-analyses and systematic reviews have
investigated the effects of Ginkgo biloba [13], zinc supplementationA
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significant benefit in tinnitus treatment. Some of those interventions
were designed for management to specific situation (i.e. zinc supple-
mentation to the rationale of zinc deficiency) [14] but the others did
not [13,15]. Only melatonin [5] and intra-tympanic corticosteroid
injections [16] have shown promising results in some investigations.
Similarly, the intra-tympanic corticosteroid injection had the prefer-
ence to focus on situation of local inflammation [16]. Because there
were a lack of enough comparative evidence, the current guidelines
declined the recommendation of pharmacologic interventions for tin-
nitus management [8,9]. However, it had become more and more dif-
ficult conducting a large-scale randomized controlled trial to
multiply compare different pharmacologic interventions at a time.
Network meta-analysis (NMA) are conducted based on statistical
method to calculate the direct and indirect comparison between mul-
tiple treatments. The evidence of direct comparison enables compari-
son between original randomized controlled trials (RCTs). The
evidence of indirect comparison mainly came from the hypothesis of
transitivity, which was one of the key component of NMA. The NMA
of existing RCTs enables estimation of the comparative efficacy and
understanding of the relative merits of multiple interventions and
maximises statistical power, which cannot be done in traditional
pairwise meta-analysis. Furthermore, based on the multiple compari-
son, the network meta-analysis could provide new statistical evi-
dence to guide the future studies. Considering these issues, we
conducted an NMA of the published RCTs to estimate the relative effi-
cacy of different pharmacologic treatments in patients with tinnitus.
The PICO of the current NMA was: (1) Patient or Problem: tinnitus
patients without specific or treatable origin; (2) Intervention: phar-
macologic intervention or nutrition supplement to manage tinnitus
severity; (3) Comparator: placebo-controlled or active-controlled;
and (4) Outcome: changes of tinnitus severity.2. Methods
2.1. General guidelines of the study
The current network meta-analysis (NMA) followed an a priori
defined unpublished protocol (available upon reasonable request to
the corresponding author) and was performed according to the latest
preferred reporting items for systematic reviews and meta-analyses
(PRISMA) 2020 guideline [17] and AMSTAR2 (Assessing the methodo-
logical quality of systematic reviews) Guidelines [18]. The current
study had been approval by the Institutional Review Board of the Tri-
Service General Hospital, National Defense Medical Center (TSGHIRB
No. B-10929). The current study had been registered in PROSPERO
(CRD42020177742) with the first submission date of April 1st, 2020
and final approval of registration date by July 5th, 2020.2.2. Target of investigated medication, search strategy and selection
criteria
In order to improve the reliability of the current NMA, we choose
the pharmacologic treatments which were intended to include from
the list of recommendations in the current review articles or clinical
guidelines [1,8,9,13,1923]. A systematic review was carried out
using ClinicalKey, Cochrane CENTRAL, Embase, ProQuest, PubMed,
ScienceDirect, Web of Science, and ClinicalTrials.gov databases from
inception to April 5th, 2021 (eTable 1). No language restriction was
used. In addition, manual searches were performed for potentially
eligible articles selected from the reference lists of review articles,
clinical guidelines, and pairwise meta-analyses [1,8,9,13,1923]. The
definition of “tinnitus without specific or treatable origin” followed
the definition of primary tinnitus addressed in the important guide-
line by Tunkel, D.E. (2014) [22].Please cite this article as: J.-J. Chen et al., Efficacy of pharmacologic tr
network meta-analysis of randomised controlled trials, EClinicalMedicine2.3. Inclusion and exclusion criteria
We included published randomized controlled trials (RCTs) with
placebo-controlled, waiting-list controlled or active-controlled
design, conducted in tinnitus patients. In the initial registration in
PROSPERO, the target participants were those with chronic tinnitus
and the target of comparison was pharmacologic treatment only.
However, in order to reduce the potential heterogeneity of the
recruited participants and to expand the potential treatment strategy,
we changed to only included published RCTs to compare different
pharmacologic treatments or nutrient supplements in tinnitus
patients without specific or treatable origin. That is, in the current
NMA, non-invasive brain/nerve stimulation methods were not inves-
tigated. Further, tinnitus patients with specific or treatable origin
would not be included in the current study. The targets of compari-
son arms were set to be pharmacologic treatments or nutrient sup-
plements in patients with tinnitus. That is, in the current NMA, non-
invasive brain/nerve stimulation methods were not investigated.
The exclusion criteria were [1] not a clinical trial, [2] not an RCT,
[3] not reporting the target outcomes (defined below), [4] not related
to pharmacologic treatment or nutrient supplements mentioned ear-
lier and [5] studies investigating central or peripheral non-invasive
brain/nerve stimulation therapy. In cases of duplicated usage of data
(i.e., different articles based on the same sample sources), we
included only the article with the largest sample source. In addition,
the network meta-analysis was based on two KEY hypotheses (i.e.
transitivity and similarity), which had to be fulfilled by the good ran-
domization. It will violate these important hypotheses of network
meta-analysis if we included the study with poor randomization [i.e.
had significantly different baseline tinnitus severity between the
groups after randomization]. In order to improve the quality of simi-
larity/transitivity hypothesis, we excluded those poor randomization
RCTs with significantly different severity in baseline.
2.4. Data extraction
Three authors (JJ Chen, YW Chen and BY Zeng) independently
screened the studies and extracted the relevant information from the
manuscripts. In cases of discrepancy, the corresponding author (PT
Tseng) mediated. If data of outcomes of interest were missing from
published reports, the corresponding authors or co-authors were
approached to obtain the additional data. If the data of outcomes of
interest still were unavailable, we will only count the other available
outcomes of interest from this RCT in the network meta-analysis of
other outcomes. We followed an a priori defined unpublished proto-
col (available upon reasonable request to the corresponding author)
and the flowchart used in previous NMAs [11,2430].
2.5. Outcomes
2.5.1. Primary outcome
The primary outcome was change in the severity of tinnitus after
treatment in patients with tinnitus.
2.5.2. Secondary outcomes
Secondary outcomes were change in quality of life and response
rate related to the treatment in patients with tinnitus. The response
rate was defined on the basis of the criteria applied in the included
studies. Finally, we assessed the dropout rate, which was defined as
the percentage of patients dropping out for any reason before study
completion.
2.6. Cochrane risk-of-bias tool and Grade ratings
Three independent authors (JJ Chen, YW Chen and BY Zeng) eval-















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































JID: ECLINM [m5G;August 13, 2021;13:40]
Please cite this article as: J.-J. Chen et al., Efficacy of pharmacologic treatment in tinnitus patients without specific or treatable origin: A
network meta-analysis of randomised controlled trials, EClinicalMedicine (2021), https://doi.org/10.1016/j.eclinm.2021.101080






















































































































































































































































































































Pairwise (upper-right portion) and network (lower-left portion) meta-analysis results are presented as estimate effect sizes for the outcome of improvement in severity of tinnitus in patients with tinnitus. Interventions are reported in order
of mean ranking of severity of tinnitus improvement, and outcomes are expressed as standardised mean difference (SMD) (95% confidence intervals). For the pairwise meta-analyses, SMD of less than zero indicates that the treatment speci-
fied in the row realized more improvement than that specified in the column. For the network meta-analysis (NMA), SMD of less than zero indicates that the treatment specified in the column realized more improvement than that specified
in the row. Bold results marked with * indicate statistical significance.
Abbreviation: 95%CIs: 95% confidence intervals; Aca: acamprosate; Alp: alprazolam; ALVitC: alpha-lipoic acid plus vitamin C; Ami: amitriptyline; Bet: betahistine; Car: carbamazepine; Chl: chlorpheniramine; ClD: clonazepam plus deanxit;
CLES: common language effect size; Clo: clonazepam; DeGin: intra-tympanic dexamethasone injection plus ginkgo biloba; DeLid: intra-tympanic dexamethasone injection plus lidocaine; DeMel: intra-tympanic dexamethasone injection
plus melatonin; Dex: intra-tympanic dexamethasone injection; Gab: gabapentin; GABA: gamma-Aminobutyric acid; GaLid: gabapentin plus intradermal lidocaine injection; Gin: ginkgo biloba; GRADE: Grading of Recommendations Assess-
ment, Development and Evaluation; KRG: Korean red ginseng; Mel: melatonin alone; MeSul: melatonin and sulodexide; Met: intra-tympanic methylprednisolone injection; Mis: misoprostol; Ner: neramexane; NMA: network meta-analy-
sis; Nor: nortriptyline; Oxc: oxcarbazepine; Ozone: ozone exposure; Par: paroxetine; PaVitE: papaverine hydrochloride plus vitamin E; Pen: pentoxifylline; Pir: piribedil; Pla: placebo; Pra: pramipexole; PRISMA: Preferred Reporting Items
for Systematic Reviews and Meta-Analyses; RCT: randomised controlled trials; RR: rate ratio; Ser: sertraline; SMD: standardized mean difference; SUCRA: surface under the cumulative ranking curve; THI: tinnitus handicap inventory; Tra:
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6 J.-J. Chen et al. / EClinicalMedicine 00 (2021) 101080described in the Cochrane risk-of-bias tool [31]. We evaluated the
certainty of the evidence, including transitivity, precision, and coher-
ence, according to the GRADE framework and the article by Cipriani,
et al. [32,33]
2.7. Statistical analysis
We estimated the standardised mean difference (SMD) with a 95%
confidence interval (95%CIs) for continuous variables (i.e., the pri-
mary outcome of tinnitus severity and the secondary outcome of
quality of life). For the categorical variables, we used the rate ratio
(RR) and 95%CIs (i.e., the secondary outcome of response rates and
drop-out rate) and applied a 0.5-zero-cell correction during the
meta-analysis procedure. However, if zeroes were present in both
the intervention and control arms of one study, we did not apply
such a correction procedure because of the risk of increasing the bias;
instead, such studies were excluded from our analysis [34,35]. We
used the frequentist model of NMA to compare the effect sizes of
studies with similar interventions. All comparisons were performed
using a two-tailed t-test, and p < 0.05 was considered statistically
significant. Heterogeneity among the included studies was evaluated
using the tau value, which is the estimated standard deviation of the
effect across the included studies.
We used mixed comparison with generalised linear mixed models
to make direct and indirect comparisons [36]. To compare multiple
treatment arms, we combined direct and indirect evidence from the
included studies [37]. STATA version 16.0 (StataCorp LLC Statistics/
Data Analysis StataCorp, TX, USA) was used in our NMA with the
mvmeta command [38]. The restricted maximum likelihood method
was used to evaluate the between-study variance [39]. To provide
additional information for clinical applications, we calculated the rel-
ative ranking probabilities of the treatment effects of all treatments
for the target outcomes. In brief, the surface under the cumulative
ranking curve (SUCRA) indicated the percentage of the mean rank of
each treatment relative to an imaginary intervention that was the
best without uncertainty [40]. When the area under the curve was
smaller, the treatment deserved a higher rank of benefit in the treat-
ment of tinnitus.
We evaluated the potential inconsistencies between the direct
and indirect evidence within the network by using the loop-specific
approach and identified local inconsistencies by using the node-split-
ting method. The design-by-treatment model was used to evaluate
global inconsistencies across the entire NMA [41]. We used the com-
parison adjusted funnel plot and Egger regression to evaluate the
potentially small study effects in the order of efficacy of individual
treatments [42]. Finally, following the rationale of previous NMA
study [43], we assessed the efficacy of the different kinds of placebo
therapy or control (treatment as usual or waiting list) as additional
proof of transitivity by computing the severity of tinnitus (Hedges’ g)
and response rate (event rate) for an oral form of placebo therapy,
injection form of placebo therapy, and controls (treatment as usual or
waiting list) on the platform of Comprehensive Meta-Analysis soft-
ware, version 3 (Biostat, Englewood, NJ). If significant evidence of dif-
ferent effects of placebo therapy or control (treatment as usual or
waiting list) by specific placebo therapy/control was found [44], we
arranged sensitivity tests by removing the trial(s) of that specific pla-
cebo therapy/control and repeated the main analysis. In addition, in
order to investigate the potential impact of different disease duration
of the tinnitus symptom on the current NMA, we arrange further
evaluation of the potential different placebo effect in the subgroups
of different disease duration of the tinnitus symptom as additional
proof of transitivity. In order to reduce the potential heterogeneity of
the study design, we arranged subgroup analysis focusing on RCTs
with placebo-controlled. Finally, in order to improve the methodol-
ogy reliability of the included RCTs, we arranged subgroup analysis
focusing on RCTs with multiple domain rating scales, such as tinnitusPlease cite this article as: J.-J. Chen et al., Efficacy of pharmacologic tr
network meta-analysis of randomised controlled trials, EClinicalMedicinehandicap inventory, tinnitus handicap questionnaire, and tinnitus
severity index.
2.8. Role of funding source
None of the funding source had any role in study design and/or
data analysis or interpretation.
3. Results
A total of 87 articles were considered for full-text review (Fig. 1),
of which 51 were excluded for various reasons (eTable 2). Finally, 36
articles were included in the current study (eTable 3). Fig. 2 depicts
the entire geometric distribution of the treatment arms. To be spe-
cific, in the Fig. 2, the lines between nodes represent direct compari-
sons in various trials, and the size of each circle is proportional to the
size of the population involved in each specific treatment. The thick-
ness of the lines is proportional to the number of trials connected to
the network.
3.1. Characteristics of the included studies
A total of 2761 participants were included, with mean
age = 52.3 years (range: 39.0 to 72.6 years) and mean female
proportion = 45.5% (range: 10.7 to 65.9%). The mean treatment duration
was 11.9 weeks (range: 2 to 24 weeks). The baseline characteristics of
the included participants are summarised in eTable 3. The definition of
response varied among the recruited studies: subjective relief, Tinnitus
Handicap Inventory improvement at least 1/3 from baseline, Visual Ana-
logue Scale reduction >50%, 15 dB or greater decrease in loudness from
baseline, increase in global improvement of at least 4, THI less than 36,
THI reduction of more than 10 or improvement of 20 points or more in
tinnitus handicap questionnaire scores.
3.2. Risk of bias, publication bias, inconsistency assessment, and grade
ratings
We found that 66.7% (168/252 items), 25.8% (65/252 items) and
7.5% (19/252 items) of the included studies had a low, unclear, and
high risk of bias, respectively. Unclear reporting of ‘Allocation con-
cealment’ and ‘Blinding of outcome assessment’ were the most often
encountered reasons for unclear risk of bias (eFigure 4A-4B).
Funnel plots of the publication bias (eFigure 5A5H) revealed
general symmetry, and the results of Egger’s test indicated no signifi-
cant publication bias among the articles included in the NMA. In gen-
eral, the NMA did not demonstrate inconsistencies in terms of either
loop-specific approach, node-splitting method, or design-by-treat-
ment method (eTable 67). The results of GRADE evaluation have
been listed in the appendix. In brief, the overall quality of evidence of
the overall NMA, direct evidence, and indirect evidence were low to
medium (eTable 8).
3.3. Primary outcome: Change in tinnitus severity
Changes in tinnitus severity for all treatments can be found in
Table 1/Fig. 3. The NMA revealed that the oral amitriptyline, oral
acamprosate, and oral gabapentin plus intradermal lidocaine injec-
tion were associated with significant improvement in the severity of
tinnitus in comparison to the placebo/control (Table 1 and Fig. 3).
According to the SUCRA, oral amitriptyline was associated with the
largest improvement, followed by oral acamprosate and oral gaba-
pentin plus intradermal lidocaine injection (eTable 4A). Finally, the
heterogeneity among the included studies did not reveal any signifi-
cant heterogeneity detected using the tau value (eTable 9).
There was no significant different placebo effect between the
injection form placebo, oral form placebo, and controls withouteatment in tinnitus patients without specific or treatable origin: A
(2021), https://doi.org/10.1016/j.eclinm.2021.101080
Fig. 1. Flowchart of the current network meta-analysis. Fig. 1 depicts the entire flowchart of the current network meta-analysis.
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J.-J. Chen et al. / EClinicalMedicine 00 (2021) 101080 7placebo (i.e. waiting-list) (p = 0.97, eFig. 3A). However, if we exam-
ined the individual placebo effect in specific placebo group, we
detected a significant placebo effect in the oral form of placebo ther-
apy (p < 0.001). Furthermore, the main result of primary outcome
would not change after removing non-placebo controlled trials
(eFig. 1D and eFig. 2D).
About the subgroup of different disease duration of tinnitus symp-
tom, there was no significant different placebo effect between the
subgroups of disease duration 12 months, 23 months, 36
months, 612 months, and > 12 months (p = 0.80, eFig. 3B).Fig. 2. Network structure of changes in severity of tinnitus. Fig. 2 depicts the overall
network structure of the current network meta-analysis of changes in severity of tinni-
tus. The lines between nodes represent direct comparisons in various trials, and the
size of each circle is proportional to the size of the population involved in each specific
treatment. The thickness of the lines is proportional to the number of trials connected
to the network.
Please cite this article as: J.-J. Chen et al., Efficacy of pharmacologic tr
network meta-analysis of randomised controlled trials, EClinicalMedicineHowever, if we examined the individual placebo effect in specific
subgroup, we detected a significant placebo effect in the subgroup of
tinnitus symptoms disease duration between 6 and 12 months
(p = 0.02).
Finally, in the subgroup analysis focusing on RCTs with multiple
domain rating scales, the main results of superiority rankings
revealed similar findings. To be specific, the intradermal lidocaine
injection plus oral gabapentin (GaLid) were associated with signifi-
cant improvement in the severity of tinnitus in comparison to the
placebo/control (SMD=0.75, 95%Cis: 1.39 to 0.11) (eTable 5D,Fig. 3. Forest plot of the changes in severity of tinnitus. Fig. 3 indicates that, when the
effect size is less than zero, the specified treatment was associated with higher
improvement in severity of tinnitus than placebo/controls did.
eatment in tinnitus patients without specific or treatable origin: A
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8 J.-J. Chen et al. / EClinicalMedicine 00 (2021) 101080eFig. 1F, and eFig. 2F). According to the SUCRA, the GaLid was associ-
ated with the largest improvement (eTable 4E).
3.4. Secondary outcome: Response rate and change in quality of life
The NMA revealed that intra-tympanic dexamethasone injection
plus oral melatonin, oral melatonin plus sulodexide, oral melatonin
alone, oral amitriptyline, oral acamprosate, zinc supplementation,
and oral gabapentin plus intradermal lidocaine injection were associ-
ated with significantly higher response rates than the placebo/control
was (eTable 5A, eFig. 1A, and eFig. 2A). According to the SUCRA, intra-
tympanic dexamethasone injection plus oral melatonin was associ-
ated with the highest response rate, followed by oral melatonin plus
sulodexide and oral melatonin alone (eTable 4B).
Regarding assumptions of transitivity, there was no significant
difference between the investigated placebo therapy/waiting-list
groups (p = 0.79, eFig. 3C). Furthermore, the main result of secondary
outcome would not change after removing non-placebo controlled
trials (eFig. 1E and eFig. 2E). To provide a more clinical-relevant infor-
mation to clinicians, we transformed the response rate into Common
Language Effect Size (CLES). To be specific, the value of CLES repre-
sent the probability of one random observation from the treated pop-
ulation being larger than another random observation from the
control population [45]. The application of CLES would help the clini-
cians to communicate with ordinary people more easily. The calcu-
lated CLES of response rates of control without placebo, injection
form placebo, and oral form placebo were 16.9%, 26.4%, and 24.5%
respectively. That is, the prescription of injection form placebo and
oral form placebo will have the probability of 26.4% and 24.5% to get
response for tinnitus symptoms.
On the other hand, none of the investigated pharmacologic treat-
ments were associated with a significant difference in the outcome of
quality of life in patients with tinnitus in comparison to the placebo/
control groups (eTable 4C, eTable 5B, eFig. 1B, and eFig. 2B).
3.5. Dropout rate
In the NMA, none of the investigated pharmacologic interventions
were associated with significantly different dropout rates compared
to placebo/control. (eTable 4D, eTable 5C, eFig. 1C, and eFig. 2C).
4. Discussion
To our knowledge, this is the first NMA addressing the efficacy of dif-
ferent pharmacologic management in tinnitus without specific/treatable
origin (i.e. primary tinnitus). Themain findings of the current NMAwere
that regimens of pharmacologic interventions with brain-acting effect,
such as amitriptyline, acamprosate, gabapentin, and melatonin, were
associated with significantly better improvement in tinnitus severity or
response rate than the placebo/waiting-list groups. Several mechanisms
support the effects found in this NMA. Another important finding of the
current NMA was the significantly higher response rate of intra-tym-
panic dexamethasone injection plus oral melatonin than the placebo/
waiting-list group. Most treatments showed similar drop-out rate com-
pared to placebo/control.
The severe tinnitus perception exerted similar abnormal neuro-
transmitter secretion found in the pain perception in the somatosen-
sory system, which was associated with decreased GABAergic
inhibition [46]. Therefore, the prescription of gabapentin, which
bound at calcium channel proteins and exerted widely suppressing
effect, could imitate the GABAergic effect [47]. Similarly, the amitrip-
tyline, one of the tri-cyclic antidepressant family, had been found to
exert its role on nociceptive perception in the central somatosensory
system through multiple neurotransmitter system, such as GABA and
alpha1-adrenergic receptors [48]. In addition to the theory of abnor-
mal nociceptive perception, the previous systematic review andPlease cite this article as: J.-J. Chen et al., Efficacy of pharmacologic tr
network meta-analysis of randomised controlled trials, EClinicalMedicinenetwork meta-analysis had demonstrated that tinnitus patients with-
out specific or treatable origin had been found to have significant
hyperactivity in brain multiple regions [11]. Therefore, the strategy
to reduce the abnormal hyperactivity would exert potential beneficial
effects to reduce tinnitus severity. For example, the acamprosate is
thought to stabilize chemical signaling in the brain through blocking
glutaminergic N-methyl-D-aspartate receptors and GABA receptors
[49], which efficacy in improving tinnitus would reflect the potential
new direction for guiding future research of tinnitus management.
Another important finding of the current NMA was the signifi-
cantly higher response rate of intra-tympanic dexamethasone injec-
tion plus oral melatonin than the placebo/waiting-list group.
Melatonin has both dopaminergic antagonist effects [50] and anti-
oxidant effects [51]. The description of the tinnitus auditolimbic
dopaminergic pathway, located within the prefrontal, primary tem-
poral, temporoparietal associative areas and the limbic system [6],
share cerebral structures with tinnitus perception; thus it was con-
sidered a novel approach to tinnitus management [52]. The overt oxi-
dative stress [5] and imbalance antioxidant enzyme [7] is considered
one possible etiology of tinnitus. The supplementation of antioxi-
dants such as melatonin has been shown to be effective in tinnitus
management [53]. Although the findings of potential benefits of mel-
atonin in tinnitus management could support the hypothesis of a tin-
nitus auditolimbic dopaminergic pathway and overt-oxidative stress
in tinnitus, future clinical trials should focus on the etiology of tinni-
tus.
Based upon the hypothesis of triggers of cochlear damage to the
early development of tinnitus [54], an intra-tympanic steroid injec-
tion (i.e., dexamethasone) theoretically is a promising treatment
modality for early-stage tinnitus with origin of cochlear damage [55].
The beneficial effects of dexamethasone on tinnitus might be derived
from immune suppression, anti-inflammation and sodium reabsorp-
tion in the inner ear through action on steroid receptors in the human
temporal bone [55]. The intra-tympanic administration route could
result in regionally high peri‑lymphatic dexamethasone levels com-
pared to a systematic administration route, which could reduce the
risk of systemic adverse events [55]. However, since the current NMA
recruited tinnitus patients without specific or treatable origin, the
potential beneficial effect of intra-tympanic dexamethasone injection
alone did not achieve significant level (Fig. 3). Therefore, combined
with the findings in the current NMA, the intra-tympanic dexametha-
sone injection plus oral melatonin would be ranked superior to the
intra-tympanic dexamethasone injection alone in tinnitus patients
without specific or treatable origin.
In comparison with the previous clinical guidelines [8,9,22], the cur-
rent NMA did not focus on the traditional management (i.e. tinnitus
support and psychologic therapy) to tinnitus, which was relatively
time-consuming and expensive. Rather, the current NMA focus on the
pharmacologic interventions to manage the tinnitus severity. In addi-
tion, the current NMA also focus on the potential placebo effect in the
tinnitus management. To be specific, the current NMA found that the
oral form placebo exerted significantly beneficial effects in participants
with tinnitus (p< 0.001) (eFig. 3A). However, the CLES of response rates
of oral form placebo (i.e. the probability of one random observation
from the treated population being larger than another random observa-
tion from the control population) was only 24.5%, which was relatively
low compared to that of neuropsychiatric disease, such as depression
(i.e. 35%40%) [56]. However, the unavoidable placebo effect could also
be at least partly explained by the fact that most studies applied subjec-
tive rating scales and there was a relative lack of reliable objective inves-
tigating tools. Therefore, to develop up an conclusive objective
measurements for the severity of tinnitus without specific/treatable ori-
gin should be warranted [57].
Several potential limitations should be considered. First, this NMA
may have been underpowered due to the heterogeneity of the partic-
ipants (e.g., comorbidities, mood disorder, baseline severity ofeatment in tinnitus patients without specific or treatable origin: A
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duration in each study and follow-up duration), variety in the defini-
tion of response, variety in tinnitus severity or quality-of-life rating
scales, and high risk of bias in ‘Random sequence generation’ and
‘Blinding of participants’ in some of the included RCTs. In order to
overcome the potential bias on the primary outcome, we arranged
subgroup to exclude RCTs without placebo-control, in which the
main results would not change. Further, in the subgroup of different
duration of tinnitus symptoms, there was no significant difference of
placebo effect between the subgroups with different disease duration
of tinnitus symptom (p = 0.80), which suggest potentially less impact
by the different duration of tinnitus symptom on the primary out-
come. As for the heterogeneity of the outcome reporting (i.e. variety
in tinnitus severity or quality-of-life rating scales), this was an
unavoidable limitation of any NMA investigating subjective out-
comes. The tinnitus, just like the depressive symptoms, quality of life,
or pain symptoms [58], was a subjective symptom and lack of objec-
tive measurement to measure its severity or to define its treatment
response. Currently, there had not been any conclusive golden rating
scales to measure its severity [8,9]. Also, there had been no conclusive
evidence to approve the superiority of one rating scales to the others
[8,9,22]. The choice or selection of one specific rating scales would
become an potential source of bias in the network meta-analysis of
subjective symptoms. Based on this limitation, we highly recommend
future studies to address the need for a gold standard measurement
of tinnitus severity, which would appear to be a significant limitation
in the tinnitus research field. Further, the results of the future study
would be recommended to be rated according to a standardized
multi-measure scale. Therefore, the clinicians may pay attention
when applied the results of current study in their clinical practice
because of the potential difference between the rating scales and the
variety of definition of response rate. Second, although the most of
the RCTs included a placebo control in their study design, some of the
included trials applied waiting list as their control groups. However,
the main findings were unchanged after excluding those trials
(eFig. 1D-1E and 2D-2E). Third, given the relatively small number of
patients and RCTs, the main results of this NMA should perhaps be
conservatively applied in clinical practice. Fourth, despite some het-
erogeneity among RCTs regarding the control group, when trials
were restricted to an oral form of placebo therapy, results were simi-
lar. Further, the potential placebo effect was an unavoidable issue in
any clinical studies investigating disease of subjective symptoms,
such as tinnitus. The overall placebo of the injection form placebo
and oral form placebo were 26.4% and 24.5%, which was relatively
low compared to that of neuropsychiatric disease, such as depression
(i.e. 35%40%) [56]. Fifth, because of small numbers of included RCTs
and insufficient direct/indirect comparison between treatment arms,
there would be different findings between the primary outcome (i.e.
changes of tinnitus severity) and secondary outcome (i.e. response
rate). Sixth, although the De Ridder et al. (2021) [4] had provided the
clear concept of “tinnitus disorder”, the most included RCTs (pub-
lished from 1993 to 2020) in the current NMA did not apply the con-
cept of “tinnitus disorder”. Therefore, we could not make distinguish
between the target of “tinnitus vs tinnitus disorder” in the current
study. Finally, we only investigated the drop-out rate but not by an
adverse events profile because too few studies provided data about
adverse events to form a network. Also, there were some other
important factors associated with the baseline tinnitus severity, such
as quality of life, anxiety mood, depressive mood, and so on. How-
ever, we could only perform network meta-analysis of quality of life
but not the others because there were too few RCTs providing such
data to form a network structure.
In conclusion, this NMA found that pharmacologic interventions
with brain-acting effects (i.e., amitriptyline, acamprosate, and gaba-
pentin) and those with anti-inflammation/anti-oxidant effect (i.e.,
intra-tympanic dexamethasone injection plus oral melatonin) werePlease cite this article as: J.-J. Chen et al., Efficacy of pharmacologic tr
network meta-analysis of randomised controlled trials, EClinicalMedicineassociated with superior improvement in tinnitus severity and
response rate compared to placebo/control in tinnitus patients with-
out specific or treatable origin. The main results did not change when
focusing RCTs with placebo-controlled. Most treatments showed sim-
ilar drop-out rate compared to placebo/control. However, because
some of the intervention comparisons were based on only a few RCTs
and the rating scales of tinnitus severity and other subjective symp-
toms had widely varied, clinicians should select specific treatments
with caution. Based on the statistical result found in the current
NMA, we would like to recommend future RCTs investigating brain-
acting regimens/modulations targeting abnormal brain hyperactiv-
ities and overt oxidative stress in tinnitus without specific or treat-
able origin.
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